Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3

被引：0
|
作者：
Papp, K. [1 ]
Leonardi, C. [2 ]
Blauvelt, A. [3 ]
Korman, N. [4 ]
Ohtsuki, M. [5 ]
Reich, K. [6 ,7 ]
Mallbris, L. [8 ]
Ball, S. [8 ]
Erickson, J. [8 ]
Griffiths, C. E. [9 ]
机构：
[1] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan
[6] Dermatol Hamburg, Hamburg, Germany
[7] Georg August Univ, Hamburg, Germany
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Univ Manchester, Manchester, Lancs, England
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
058
引用
收藏
页码：S170 / S170
页数：1
相关论文
共 50 条
  • [21] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [22] Impact of ixekizumab treatment on scalp psoriasis: results from the placebo-controlled induction period of UNCOVER-3
    Reich, K.
    Leonardi, C.
    Lebwohl, M.
    Romiti, R.
    Goldblum, O.
    Zhang, L.
    Shrom, D.
    Dennehy, E.
    Sofen, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 73
  • [23] Efficacy and safety of ixekizumab in psoriasis patients who failed to reach PASI 75 on etanercept: subanalysis of UNCOVER-3
    Blauvelt, A.
    Papp, K.
    Puig, L.
    Dutronc, Y.
    Kerr, L.
    Mallbris, L.
    Ilo, D.
    Weisman, J.
    Augustin, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 18 - 19
  • [24] Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
    Papp, Kim
    Puig, Lluis
    Dutronc, Yves
    Kerr, Lisa
    Mallbris, Lotus
    Ilo, Dapo
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB257 - AB257
  • [25] Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)
    Imafuku, Shinichi
    Torisu-Itakura, Hitoe
    Nishikawa, Atsushi
    Zhao, Fangyi
    Cameron, Gregory S.
    JOURNAL OF DERMATOLOGY, 2017, 44 (11): : 1285 - 1290
  • [26] Safety profile of patients achieving complete or near complete resolution of moderate-to-severe psoriasis after 12 weeks of etanercept or ixekizu-mab: Integrated analyses from UNCOVER-2 and UNCOVER-3
    Blauvelt, Andrew
    Griffiths, Christopher E. M.
    Lebwohl, Mark
    Puig, Lluis
    Ball, Susan
    Warner, Margaret
    Zhang, Lu
    Dey, Debashish
    Mallbris, Lotus
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB269 - AB269
  • [27] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
    Warren, R. B.
    Cather, J.
    Ohtsuki, M.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
  • [28] Sustained high level of efficacy and favorable safety of ixekizumab in psoriasis: 4 years of follow-up from UNCOVER-3
    Lebwohl, Mark G.
    Gordon, Kenneth B.
    Paul, Carle
    Gallo, Gaia
    Zhang, Lu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB128 - AB128
  • [29] Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
    Egeberg, Alexander
    Kristensen, Lars Erik
    Vender, Ron
    Zaheri, Shirin
    EL Baou, Celine
    Gallo, Gaia
    Riedl, Elisabeth
    Schuster, Christopher
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [30] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
    Blauvelt, Andrew
    Gooderham, Melinda
    Iversen, Lars
    Ball, Susan
    Zhang, Lu
    Agada, Noah O.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 855 - 862
12345